Lyllana Patch, Extended Release
Product Images NDC 65162-149

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Lyllana (NDC 65162-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Lyllana Estradiol Transdermal System 1)

Chemical structure diagram of estradiol, the active ingredient in LYLLANA transdermal patches. The structure shows a steroid backbone with hydroxyl groups and methyl group as part of the molecular layout.*

FDA Label Image

Figure D (Lyllana Estradiol Transdermal System 10)

An instructional drawing showing two hands peeling apart a transdermal patch, illustrating how to remove the protective liner from a patch, likely corresponding to the LYLLANA estradiol extended-release transdermal patch.*

FDA Label Image

Figure E (Lyllana Estradiol Transdermal System 11)

An instructional line drawing showing a person applying a round transdermal patch to the lower abdomen just above the hip area, indicating placement for a patch medication like LYLLANA (estradiol) extended-release patches.*

FDA Label Image

Figure F (Lyllana Estradiol Transdermal System 12)

Illustration showing the application of a LYLLANA estradiol transdermal patch on the lower abdomen of a person, demonstrating proper placement for extended-release hormone delivery.*

FDA Label Image

Figure G (Lyllana Estradiol Transdermal System 13)

An instructional illustration showing hands applying or removing a rectangular patch from skin, likely depicting the use of a transdermal medication patch. It includes close-up views of fingers handling the patch on a curved part of the body.*

FDA Label Image

0.025 mg/day Pouch (Lyllana Estradiol Transdermal System 14)

Label for LYLLANA estradiol transdermal system delivering 0.025 mg/day. The patch system size is 1.89 cm², containing 0.314 mg of estradiol USP. The patch includes acrylic and silicone adhesives and is distributed by Amneal Pharmaceuticals LLC. The label includes storage instructions and usage warnings.*

FDA Label Image

0.025 mg/day Carton (Lyllana Estradiol Transdermal System 15)

LYLLANA (estradiol transdermal system, USP) delivers 0.025 mg/day in a transdermal patch form. The unfolded carton image shows labeling with Amneal Pharmaceuticals LLC as the labeler, highlighting package contents of 8 systems. The label includes application instructions, storage directions, and safety information related to the estradiol-containing patch.*

FDA Label Image

0.0375 mg/day Pouch (Lyllana Estradiol Transdermal System 16)

LYLLANA estradiol transdermal system patch delivering 0.0375 mg/day. The label indicates each 2.83 cm² patch contains 0.470 mg estradiol. It lists inactive components and storage instructions. Distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ. Rx only.*

FDA Label Image

0.0375 mg/day Carton (Lyllana Estradiol Transdermal System 17)

Packaging label for LYLLANA (estradiol transdermal system, USP) delivering 0.0375 mg/day. The label shows the carton design by Amneal Pharmaceuticals LLC, including directions for use with a weekly application schedule. It indicates a pack of 8 systems and includes NDC 65162-148-08 and storage instructions with tamper-evident features.*

FDA Label Image

0.05 mg/day Pouch (Lyllana Estradiol Transdermal System 18)

Label for LYLLANA 0.05 mg/day estradiol transdermal patch system. The label specifies the patch size as one 3.78 cm² system delivering 0.627 mg estradiol. It includes inactive ingredients, storage instructions, and distributor information for Amneal Pharmaceuticals LLC, Bridgewater, NJ. The label also features the Amneal logo and a barcode.*

FDA Label Image

0.05 mg/day Carton (Lyllana Estradiol Transdermal System 19)

LYLLANA 0.05 mg/day (estradiol transdermal system, USP) packaging label from Amneal Pharmaceuticals LLC. The label states that the patch delivers 0.05 mg of estradiol per day and includes 8 systems per carton. It includes application schedule instructions and storage information, highlighting that the patch is an extended-release transdermal dosage form. The label features the Amneal logo and is designed with a white and pink color scheme.*

FDA Label Image

3 Layers (Lyllana Estradiol Transdermal System 2)

An illustration showing a cross-sectional view of the LYLLANA estradiol transdermal patch. The diagram labels three layers: the backing, the adhesive containing estradiol, and the protective liner.*

FDA Label Image

0.075 mg/day Pouch (Lyllana Estradiol Transdermal System 20)

LYLLANA estradiol transdermal system patch delivering 0.075 mg/day. The label specifies one 5.66 cm² system containing 0.940 mg estradiol. It lists inactive components and storage instructions, and indicates the product is distributed by Amneal Pharmaceuticals LLC.*

FDA Label Image

0.075 mg/day Carton (Lyllana Estradiol Transdermal System 21)

LYLLANA 0.075 mg/day estradiol transdermal system extended-release patch carton by Amneal Pharmaceuticals LLC. The package contains 8 system patches delivering 0.075 mg of estradiol daily via transdermal route. The carton includes an application schedule to guide weekly patch changes and usage instructions. The label shows the NDC 65162-150-08 and mentions the transdermal system USP compliance.*

FDA Label Image

0.1 mg/day Pouch (Lyllana Estradiol Transdermal System 22)

Label for LYLLANA estradiol transdermal system delivering 0.1 mg/day. The patch system covers 7.55 cm² and contains 1.253 mg of estradiol, USP. Includes inactive components and storage instructions. Distributed by Amneal Pharmaceuticals LLC.*

FDA Label Image

0.1 mg/day Carton (Lyllana Estradiol Transdermal System 23)

Packaging label for LYLLANA (estradiol transdermal system, USP) delivering 0.1 mg/day in a patch extended-release dosage form. The label shows the Amneal Pharmaceuticals LLC logo and NDC 65162-228-08. It includes instructions for application scheduling, usage reminders, storage conditions, and important patient safety information. The product is Rx-only and distributed by Amneal Pharmaceuticals LLC.*

FDA Label Image

Figure 1 (Lyllana Estradiol Transdermal System 3)

A line graph showing serum concentration (pg/mL) over time (days) for three different dosing strengths of LYLLANA estradiol transdermal patches: 0.1 mg/day, 0.05 mg/day, and 0.025 mg/day. The serum concentration rises after application, peaks, then gradually declines over several days for each dose level.*

FDA Label Image

Figure 2 (Lyllana Estradiol Transdermal System 4)

A bar chart comparing mean changes from baseline between Vivelle 0.0375 mg/day and placebo over 12 weeks, showing mean reductions with standard deviations and sample sizes at weeks 4, 8, and 12. The chart notes statistically significant differences between Vivelle and placebo (p<0.05).*

FDA Label Image

Figure 3 (Lyllana Estradiol Transdermal System 5)

A line graph showing the percentage change from baseline over treatment duration at weeks 26, 52, 78, and 104. The graph compares Vivelle estradiol patches at doses of 0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, and 0.025 mg/day, against a placebo. Each treatment group is represented by a distinct line, depicting trends in percentage change over time.*

FDA Label Image

Figure 4 (Lyllana Estradiol Transdermal System 6)

Line graph showing percentage change from baseline over treatment duration in weeks (26, 52, 78, 104) for Vivele transdermal patches at doses 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.1 mg/day, and placebo. The graph includes statistical significance notes comparing treatment groups to placebo.*

FDA Label Image

Figure A (Lyllana Estradiol Transdermal System 7)

Packaging components of LYLLANA estradiol transdermal system, USP delivering 0.025 mg/day. The image shows a carton with the product name, strength, and labeler Amneal Pharmaceuticals LLC. Included are informational materials such as a patient information/prescribing information leaflet (PI/PPI), a calendar for application tracking, and a pouch containing the transdermal patch.*

FDA Label Image

Figure B (Lyllana Estradiol Transdermal System 8)

An illustrated instructional diagram showing a hand using a pen to fill out an application schedule on the inside flap of a LYLLANA estradiol transdermal system patch box. The diagram emphasizes scheduling the patch application days, referencing specific days of the week, to guide proper use.*

FDA Label Image

Figure C (Lyllana Estradiol Transdermal System 9)

An instructional illustration showing hands peeling back the backing from a LYLLANA (estradiol transdermal system USP) 0.025 mg/day patch, demonstrating how to properly open the packaging before application.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.